drugset / Trial / NCT01262261

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261

Phase 3 Completed 85 enrolled Titan Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-label, re-treatment study that will confirm the safety and efficacy of Probuphine in patients who have previously completed the 6-month PRO-806 study with either Probuphine, placebo or sublingual buprenorphine.

Timeline

Start
2010-11
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified Subcutaneous

Indications